IMMUNEERING CORP - CLASS A(NASDAQ:IMRX) stock News

On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a trial to include three additional combination arms. Updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows: As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a

5 months ago - Immuneering Corporation

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

5 months ago - Immuneering Corporation

IMMUNEERING CORP - CLASS A (IMRX) Stock News

IMRX Latest News, Press Relases and Analysis

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Is Immuneering Stock Trading Higher On Tuesday?

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer